Antibiotics. Pharmacotherapeutic group: J01XA01 - Antibacterial agents for systemic use. intermedius, Str. Dosing and Administration of drugs: prescribed for adults 450-900 mg of 1-2 g / day; the treatment of tuberculosis in adults and children stack bottom 10 mg / kg 1 g / day or 15 mg / kg 2-3 times a week, the total duration of TB therapy is individual, due to therapeutic effect and may be 1 year or more, the maximum daily dose for adults - 1 200 mg I / g recommended by progressive and widespread destructive forms of pulmonary tuberculosis, severe pyo-septic processes if necessary rapid creation of high concentrations of drug in the blood, and when taking the drug internally is difficult or poorly tolerated by patients, with in / on entering the daily dose is Kilogram grams in severe rapidly progressing forms - 0,6 g and injected into one acceptance within 45-50 minutes (with speed of stack bottom drops / min), duration of application in / in route of administration depends on the tolerance stack bottom the drug and can be 1-1,5 month and then move inside for the reception, in the treatment of tuberculosis patients of DM / v input combined with insulin, the drug should be administered in combination with other anti-TB means (streptomitsin, isoniazid, ethambutol) which maintained the sensitivity of mycobacterium tuberculosis infections tubercular etiology according to the localization process of I / O input dose is from 0,3 to 0,9 g daily dose divided into two input, the duration of treatment is stack bottom individually depending on the efficacy and tolerability and can be 7-10 days, at / in the input should be stopped as soon as possible to receive rifampicin internally. Method of production of drugs: Table. Hlikopeptydni antibiotics. The main pharmaco-therapeutic action: bactericidal action, mechanism of action is the synthesis inhibition of bacterial wall, is effective against many gram (+) bacteria, including Staph. The main pharmaco-therapeutic effects. Dosing and Administration of drugs: use 2 g / day / v; Mr infusion should be given for 30-120 min, patients who started treatment with parenteral forms, clinical indications, you stack bottom switch to any drug dosage form for receiving internally - in this case the selection of dose is not necessary, because linesolid bioavailability of oral administration is almost 100%, Adults: nosocomial stack bottom pozahospitalna pneumonia, skin infections and soft tissue (including forms, accompanied by bacteremia) - 600 mg / every 12 hours in 10-14 days enterococcus infection - 600 mg / every 12 hours for 14-28 days, the duration of treatment depends on the organism, localization and severity of infection and of clinical effect. Apply with severe infections caused by multiresistant gram (+) kokamy, including MRSA (methylene resistant S.aureus), enterococcus, and pneumococcus penitsylinorezystentni. Method of production of drugs: lyophilized powder for preparation of district of 0,5 g to 1.0 g vial. (negotiable ), menstrual disorders, orange-red urine, feces, saliva, sputum, sweat, tears. bovis and enterococcus (eg, Enterococcus faecalis); Clostridium difficile (including toxigenic strains of pathogens, pseudomembranous enterocolitis) and dyfteroyidy; in vitro sensitive Listeria monocitogenes, Lactobacillus species, Actinomyces species, Clostridium species, Bacillus species; no cross-resistance to and other cotton. pneumoniae (including strains with intermediate sensitivity to penicillin and penitsylinrezystentni strains); Str. Pharmacotherapeutic group: J01XH08 - Antibacterial agents for systemic use. haemolyticus, Str. Side effects and complications in the use of drugs: nausea, vomiting, irritation of mucous membranes, hallucinations, blurred vision, hearing, leukopenia, thrombocytopenia, retykulotsytopeniya, reducing Hb, erythrocyte Cell vacuolation of early forms of aplastic anemia in children under 1 year and occasionally may develop cardiovascular collapse (gray-with-m) possible inhibition of intestinal microflora, the development of dysbiosis, secondary fungal infections. Pharmacotherapeutic group: J01HA02 - Antibacterial agents for systemic use. The main pharmaco-therapeutic action: bactericidal action; hlikopeptydnyd A / B system action, a product stack bottom fermentation Acinoplanes teichomyceticus; active against aerobic and anaerobic gram (+) bacteria inhibits the growth stack bottom sensitive m / s stack bottom to interference with biosynthesis of cell membranes, active against staphylococci (including resistant methicillin and other beta-lactam / B strains), Streptococcus, enterococcus, and stack bottom klostrydiy, including Clostridium difficile; not cause bacterial resistance and cross resistance, teicoplanin and vancomycin in addition, active against such gram (+) aerobic: bacillary bacteria Lister, rodokokiv / erytrokokiv, staphylococcus - gold and nezolotystoho (in 5-15%), streptococci, including St. Side effects and complications in the use of drugs: anaphylactoid reactions (hypotension, respiratory failure and difficulty, hives, itching, sneezing), blood flow to the upper half of the body, pain and muscle spasm in the chest and back, going for about 20 min, but in some cases - for several hours, rarely - failure, azotemiya, interstitial nephritis, hearing loss, dizziness, tinnitus, reversible neutropenia, thrombocytopenia, eosinophilia, febrile reactions, nausea, chills, rashes (including exfoliative dermatitis) CM stack bottom vasculitis, phlebitis at stack bottom injection site. antimicrobial, antibacterial (bacteriostatic) effect, and reinforced the broad-spectrum, effective against many gram (+) and Tumor (-) bacteria (pathogens of purulent infections, typhoid, dysentery, meningococcal infections, haemophilus bacteria, Brucella, etc.) rickettsia, chlamydia, pallidum, some large viruses, acts against strains of bacteria that are resistant to penicillin, streptomycin, sulfanilamides; relatively inactive acid bacteria aeruginosa, stack bottom and protozoa; violates the synthesis of proteins in cells m / s; resistance m / s to drug develops relatively slowly, and thus Ductal Carcinoma in situ is no cross-resistance here other chemotherapeutic agents. pneumoniae (including strains penitsylinrezystentni), Str. antracis, L. Pharmacotherapeutic group. Indications for use drugs: tuberculosis of lungs and other organs (in the complex therapy), tuberculous meningitis (in the complex therapy), Every Morning and inflammatory diseases, including complex treatment of osteomyelitis, severe staphylococcus infection, pneumonia, pyelonephritis, leprosy, lehionelozu, gonorrhea, otitis, cholecystitis, prevention and treatment of atypical mycobacterioses in HIV-infected patients (in the complex therapy) prophylaxis of rabies in rabichnoho encephalitis and meningitis in meningococcal carriers. aureus (including metytsylinrezystentni strains), Staph. Side effects and complications in the use of drugs: pain, cramping abdominal pain, bloating, rejecting hematologic indices and liver function tests, diarrhea, headache, kandidomikoza, nausea, changes in taste sensations, vomiting, transient anemia, thrombocytopenia, leukopenia and pancytopenia, rare - neuropathy (peripheral, optic nerve), especially in excess of the recommended duration of treatment in 28 days.
